MediumCardiologyHeart failure with reduced ejection fractionau-amcau-racp
A 72-year-old woman with long-standing hypertension and heart failure with reduced ejection fraction (LVEF 30%) presents for medication review. She is currently on perindopril 4 mg daily and frusemide 40 mg daily. She has NYHA class II symptoms and a resting heart rate of 88 beats/min in sinus rhythm. Blood pressure is 122/70 mmHg, creatinine 90 µmol/L and potassium 4.6 mmol/L. According to guideline-directed therapy, which additional medication class has the strongest evidence for reducing mortality in her condition?